Is the AstraZeneca Vaccine Approved in the U.S.?
Best COVID-19 Vaccine Stocks to Buy Now for 2021
U.K. Government Approves AstraZeneca's Coronavirus Vaccine
How to Get Help With Your Prescriptions With AstraZeneca Patient Assistance
AstraZeneca to Acquire Alexion for $39 Billion, Stock Down
Is AstraZeneca Stock Right for Your Portfolio After Alexion Announcement?
What Drugs Does AstraZeneca Make?
How Did AstraZeneca’s CVMD Franchise Perform in 2014?
In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.
Illumina Exploring In Vitro Fertilization Opportunities
Illumina is working in the reproductive health market to enhance the efficacy of in vitro fertilization tools.
AstraZeneca’s ING Franchise Saw Lower Revenues in 2014
For 2014, AstraZeneca’s ING franchise generated nearly $8.2 billion, a 8.9% decrease as compared to $9.0 billion in 2013.
Consistent Performance Measurement May Improve Novartis’s R&D
Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.
Analysts’ Expectations for Sanofi
According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
AstraZeneca’s Lynparza Gives a Strong Performance in Q1
In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported basis, driven by the drug’s rapid uptake in first-line ovarian cancer maintenance and metastatic breast cancer.
Shire Led EWU as the Healthcare Sector Rallied on December 2
On December 2, stocks at the top of the iShares MSCI United Kingdom Index were Merlin Entertainment (MERL-LON), Shire (SHP-LON) (SHPG-LON), and GlaxoSmithKline.
Recent Developments for Ionis Pharmaceuticals
On March 6, 2017, Ionis and Akcea announced positive results from the Phase III study APPROACH, evaluating volanesorsen for the treatment of patients with FCS.
AQR Capital increases stake in Intel
Intel generated ~$5.7 billion in cash from operations. The company paid quarterly dividends of $1.1 billion and repurchased 122 million shares for $4.2 billion.
Why AQR Capital exits its position in Geo Group Inc.
AQR Capital sold a position in GEO Group Inc. in 2Q14. The company accounted for a 0.0206% position in the fund’s first quarter U.S. long portfolio.
Manufacturing Production Remains Negative in the UK
With the decline in manufacturing output, the iShares MSCI United Kingdom ETF (EWU) has fallen 6.6% over the past month as of January 12.
Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16
AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.
Listing the Reasons behind Pfizer’s Discounted Price-to-Earnings
Considering the robust growth prospects for many of its products going forward, Pfizer should return to robust top line growth.
How AbbVie Fared in Q2 2018
Driven by growth in Humira, Imbruvica, and Mavyret sales, AbbVie (ABBV) delivered strong Q2 2018 results on July 27.
What Does AstraZeneca’s Growth Platform Offer?
The RI&A (respiratory, inflammation and autoimmunity) segment one of the company’s growth platforms, is a key area of development for AstraZeneca (AZN).
Analysts Give Mixed Recommendations for Novartis
Novartis’s stock price has fallen ~7.0% in the last 12 months and ~10.7% year-to-date.
Analyst Recommendations for AstraZeneca in June 2017
In 1Q17, AstraZeneca (AZN) reported revenues close to $5.4 billion, which is a fall of around 12.0% on a YoY (year-over-year) basis.
AstraZeneca’s Other Products in 3Q16
With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.
AstraZeneca and Other COVID-19 Vaccine Trials Seek Volunteers
AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.
Halliburton Company Led High-Grade Bond Issuance in November
Halliburton Company (HAL) issued A2/A rated high-grade bonds worth $7.5 billion in November.
Key Risks Facing Sucampo Pharmaceuticals in 2017
Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.
AstraZeneca Issued High-Grade Bonds to Acquire ZS Pharma
Last week, AstraZeneca issued A2/A rated high-grade bonds worth $6.0 billion to fund the acquisition of ZS Pharma (ZSPH).
Exploring Novavax’s Vaccine Candidates for RSV
According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.
What’s the Story behind the Pfizer-Medivation Deal?
Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.
AstraZeneca and Its Oncology Segment’s Growth in 2Q16
AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.
What’s to Be Expected from Novartis’s 3Q16 Earnings?
Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.
How AstraZeneca’s 1Q18 Shook Out
AstraZeneca stock has fallen ~1.2% in 1Q18, and its stock has risen ~2.1% YTD (year-to-date) as of April 6, 2018.
Bristol-Myers Squibb’s 2Q16 Estimates: Other Segments
Bristol-Myers Squibb’s (BMY) neuroscience segment is represented by the drug Abilify, while its immuno-science segment is represented by the drug Orencia.
AstraZeneca’s New Oncology Portfolio May See Healthy Growth
In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.
Merck and AstraZeneca Announced EMA Approval for Lynparza
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
Why Repatha Could Be One of Amgen’s Largest Opportunities for 2016
Despite Repatha’s slower-than-expected uptake after its launch in 2015, Amgen (AMGN) is confident of the drug’s future commercial prospects.
Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments
Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.
Understanding Bristol-Myers Squibb’s Other Segments
Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.
Why AstraZeneca’s oncology pipeline is attractive to Pfizer
Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.
Amec Foster Wheeler’s Steep Fall Pushed Down Energy Sector, EWU
Amec Foster Wheeler (AMFW) declared it will halve its dividends due to the fall in oil prices. Its trailing 5-day and trailing one-month returns were -20.1% and -28.3%, respectively, as of November 5.
How GlaxoSmithKline Stock Performed in 1Q18
GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.
Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?
Bristol-Myers Squibb’s (BMY) Opdivo’s will now share the second-line lung cancer therapy market with Roche’s Tecentriq, along with Merck’s Keytruda.
AstraZeneca’s Valuation Report Card: How Did It Score?
The fundamental factors affecting stock prices and valuation include the performance of growth platforms as well as the exclusivity of blockbuster drugs.
AstraZeneca Is Taking Steps to Improve Its Position in Oncology
During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.
How Did Novavax Perform in 2Q15?
Novavax (NVAX) posted a variety of positive qualitative and quantitative performance indicators in 2Q15.
Novartis Receives 2 Breakthrough Therapy Designations in January
In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.
Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio
In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.
Tesaro Stock Up over 16% on Rumors of Acquisition by Roche
Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.
AQR Capital initiated position in Bally Technologies Inc.
AQR Capital initiated a position in Bally Technologies during the third quarter of 2014 that accounts for 0.22% of the fund’s 3Q14 portfolio.
What Are Generic Drugs and Why Are They Important?
TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]
How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?
Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.
Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017
On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).
How Merck’s Human Vaccines Business Performed in 1Q18
In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion.
What Are Merck’s Key Growth Drivers for 2019?
Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal health businesses as its key growth drivers in 2018.
UK Stock Market Continues its Downward Momentum as EWU Lost 1.75%
On September 18, the UK stock market experienced a fall in consumer staples. The financial sector also fell steeply.
Analyzing Pfizer’s Ibrance and Xalkori after 2Q17
In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.
Investment-Grade Bond Funds Saw Outflows in November
According to Lipper’s funds flow data, investment-grade bond funds saw net outflows of $789.1 million up to the week ending November 25.
AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?
AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.
What Will Be a Key Driver of Biogen’s Future Valuations?
Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).
Why AQR Capital increased its position in Apple in 2Q14
AQR Capital increased its position in Apple from 0.86% in the previous quarter to 1.24% in the fund’s second quarter U.S. long portfolio.
AstraZeneca’s Key Focus: Oncology
AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.
AstraZeneca May Witness a Fall in 2017 Net Profit Margin
Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.
Other Drugs for Non-small Cell Lung Cancer
Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.
Four Key Deals: Analyzing Pfizer’s Impending Growth
Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.
Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017
Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Oncology Segment: Another Growth Platform for AstraZeneca?
The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.
What Might Have Fueled Valeant’s Interest in Salix?
The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.
Brodalumab, Oral Relistor among Valeant’s Recent Wins
Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.
Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines
Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.
How Has Aquinox Performed Compared to Peers?
Aquinox has a positive future outlook and will likely continue to better its performance in the near future.
Does Pfizer Deserve a Better Valuation?
Like other big pharmaceutical companies, Pfizer witnessed negative top line growth. With multiple acquisitions recently, it’s poised to grow its top line.
Performance of Novo Nordisk Stock in 2Q17
Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.
How Much Could Gilead Sciences’s Revenues Fall beyond 2016?
Gilead Sciences (GILD) is expected to garner $28.3 billion in 2017 and $26.7 billion in 2018.
Analysts’ Recommendations for Novartis on April 17
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16.
What Boosted Merck’s Stock Price on April 9
On April 9, 2018, Merck (MRK) stock rose ~4.4% in early trading and ~2.7% during the day.
Bristol-Myers Squibb: What Do Its Other Segments Offer?
Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.
Analysts’ Recommendations for GlaxoSmithKline in May
GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.
Is AstraZeneca Stock a Good Buy at These Prices?
Financials: Biggest Negative Contributor to PEUGX in 1Q16
The Putnam Europe Equity Fund – Class A (PEUGX) fell 4.3% in 1Q16, making it a below-average performer among the 12 funds in this review. In the past one year, PEUGX has fallen 7.9%
AstraZeneca Resumes COVID-19 Clinical Trials in U.K., Stock Up
Operation Warp Speed Has Invested Billions in Potential COVID-19 Vaccines
AstraZeneca Halts COVID-19 Vaccine Study After Unexplained Illness
Why the Patent Cliff Is a Key Driver of Generic Drug Growth
Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.
AstraZeneca Secures Deal With Australia for COVID-19 Vaccine
Which Biotechnology Companies Could Benefit from Brexit?
The weak pound is expected to negatively affect biotechnology companies with a high revenue exposure to the United Kingdom.
Chart in Focus: Novavax’s Financial Position in 2017
Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.
How Valeant Plans to Its Fix Dermatology Portfolio
Actions to fix dermatology portfolio After the Philidor separation, Valeant Pharmaceuticals’ (VRX) dermatology business has suffered a lot. If you want to learn more about this controversy, please read What Happened in the Valeant-Philidor Controversy? Valeant’s actions to stop the declining dermatology business include a 20-year fulfillment program with Walgreens, a newly launched prior authorization approval […]
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.
Johnson & Johnson’s Neuroscience Segment in 2017
In 4Q17, Risperdal Consta generated revenues of $197.0 million, which is an ~6.2% decline on a YoY basis.
Analyzing Eli Lilly’s Clinical and Business Developments in 1Q16
Elanco, the animal healthcare arm of Eli Lilly, received exclusive and global rights to develop and commercialize Aratana’s (PETX) Gallipart, a drug that treats osteoarthritis in dogs.
How Much Could Pfizer Grow beyond 2016?
Year-to-date, Pfizer’s (PFE) stock has already fallen 4.2%. Despite its multiple acquisitions to boost its falling top line, investors are cautious about the company.
Will Merck & Co.’s Revenue Recover in 4Q15?
Analysts’ expect Merck & Co.’s (MRK) revenue for 4Q15 to be ~$10.3 billion. It’s nearly 1.6% lower than $10.5 billion in revenue reported for 4Q14.
How AstraZeneca’s Oncology Products Performed in 4Q17
AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products.
Major Expected Events from AstraZeneca’s R&D in H2 2018
AstraZeneca has seen major recent product approvals such as Lynparza in Japan for breast cancer and Tagrisso in the EU for lung cancer.
AstraZeneca’s Expense Guidance for Fiscal 2019
In its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low single-digit percentage.